The unit has strong local partnerships with teams from IRCAN (G. Pages) and iBV (E. van Obberghen).
At the regional level, within the framework of the PACA Cancéropôle, the unit has collaborated for a long time with the pharmacokinetics department of the Marseille Faculty of Pharmacy.
At the national level, the team is coordinating multi-center clinical translational research studies (including a PHRC, among others, on securing fluoropyrimidine treatments, including meta-analyzes in partnership with Gustave Roussy, and surveys of clinical practice in partnership with the FFCD).
At the international level, the group refers to its original work on dihydropyrimidine dehydrogenase (DPD), and collaborates in this context with Professor A. Van Kuilenburg (Amsterdam, The Netherlands). Close collaboration has also been established with Professor M. Merlano’s team (Cuneo, Italy) for pre-clinical studies in particular.
NGS MiniSeq (ILLUMINA)
Droplet PCR (Bio-Rad QX200)
MassARRAY Analyzer 4 (Sequenom Agena) with chip 96 spots
LightCycler 480 (PCR quantitative), Roche, with block 96
Sequencer – Beckman CEQ 8800
UPLC-MSMS (Xevo TQD Waters)
The Oncopharmacology team at Lacassagne has published more than 300 articles in international peer-reviewed journals and regularly presents papers at major American conferences in the specialty (ASCO, AACR).
Five main publications of the last 5 years
– Van Kuilenburg AB, Etienne-Grimaldi MC, Mahamat A, Meijer J, Laurent-Puig P, Olschwang S, Gaub MP, Hennekam RC, Benchimol D, Houry S, Letoublon C, FN Gilly, Pezet D, Andre T, Faucheron JL , Abderrahim-Ferkoune A, Vijzelaar R, Pradere B, Milano G. Frequent intragenic rearrangements of DPYD in colorectal tumors. Pharmacogenomics J. 2015; 15 (3): 211-8.
-Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, Grall D, Penault-Llorca F, Dassonville O, Bertucci F, Cayre A, De Raucourt D, Geoffrey L, Finetti P, Giraud P, Racadot S, Morinière S, Sudaka A , Van Obberghen-Schilling E, Milano G. Contrasted outcomes to tumor geometry in IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res. 2012; 18 (18): 5123-33.
-Thariat J, Etienne-Grimaldi MC, Grall D, Bensadoun RJ, Cayre A, Penault-Llorca F, Veracini L, Francoual M, Formento JL, Dassonville O, De Raucourt D, Geoffrey L, Giraud P, Racadot S, Moriniere S , Milano G, Van Obberghen-Schilling E. Epidermal Growth Factor Receptor protein detection in head and neck cancer patients: a many faceted picture. Clin Cancer Res. 2012; 18 (5): 1313-1322.
-Bozec A, Sudaka A, Etienne-Grimaldi TM, Brunstein Mc, Fischel JL, Milano G. Antitumor activity of cetuximab associated with taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model. Oral Oncol. 2011; 47 (10): 940-5.
Gérard Milano, Ph D
Marie-Christine Etienne-Grimaldi, Pharmacien biologiste, Responsable Qualité du Pôle des Laboratoires
Evelyne Zanghellini, health executive
Nathalie Ebran, engineer
Patricia Formento, Senior Technician
Laurence Llorca, technician
Hedi Ben Yahia, technician
Fabienne Lopez, medical assistant